Pfizer Urges 3rd Circ. Not To Revive Lipitor Antitrust Row

By Kevin Penton ( March 22, 2016, 2:44 PM EDT) -- Pfizer and Ranbaxy urged the Third Circuit on Monday to either uphold a New Jersey federal court's dismissal of claims that it paid Ranbaxy to postpone releasing a generic of the cholesterol drug Lipitor, or to transfer the case to the Federal Circuit because it contains fraud claims involving the U.S. Patent and Trademark Office....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!